相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
100.0%
暂无批准数据
- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.
- Florida's Sunshine Genetics Newborn Screening Program will use whole-genome sequencing to screen newborns for nearly 900 rare genetic conditions, compared to the 60 conditions currently screened via standard heel-prick tests. - The pilot launches this summer at Tampa General Hospital, with planned expansion to Orlando and Miami, then statewide over five years. - Early diagnosis through genome sequencing can reduce the average five-year diagnostic odyssey, which costs over $500,000 per child, and enable early interventions including gene therapy before symptoms manifest. - The program is supported by the Sunshine Genetics Act, the Florida Institute for Pediatric Rare Diseases at FSU, and industry partner GeneDx, with strong genetic privacy protections under Florida law.
- Huxley Health Inc. has established Aerasyn Biotech as a new division focused on advancing psychedelic therapeutics through AI-guided discovery and scalable manufacturing solutions. - The company has secured up to $15 million in strategic financing and expanded its leadership team with experienced pharmaceutical and biotech executives. - Huxley's intellectual property portfolio now comprises 21 patent filings, with two provisional patents for ibogaine synthesis and manufacturing expected to be filed within the week. - The company's integrated platform combines non-hallucinogenic technologies with cost-efficient synthesis capabilities, positioning it as an infrastructure partner in the evolving psychedelics industry.
- Inimmune Corporation has appointed Ferdinand Massari, M.D., as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy to strengthen leadership ahead of Phase 2 INI-2004 allergic rhinitis data readout. - Dr. Massari brings over two decades of clinical development experience in immunology and inflammatory diseases from companies including Shire, Pfizer, Pharmacia, and Merck. - The leadership appointments support Inimmune's strategic expansion of INI-2004 development into allergic asthma and food allergy, conditions affecting millions worldwide. - Mr. McMillian contributes over 20 years of biotech finance experience, including more than $250 million in fundraising for life sciences companies and previous roles at Alexion Pharmaceuticals.
